Doig Craig L, Lavery Gareth G
Institute of Metabolism and Systems Research, University of Birmingham, 2(nd) Floor IBR Tower, Birmingham B15 2TT, UK; Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners, Birmingham B15 2TH, UK.
Institute of Metabolism and Systems Research, University of Birmingham, 2(nd) Floor IBR Tower, Birmingham B15 2TT, UK; Centre for Endocrinology, Diabetes, and Metabolism, Birmingham Health Partners, Birmingham B15 2TH, UK.
Cell Chem Biol. 2016 Dec 22;23(12):1442-1443. doi: 10.1016/j.chembiol.2016.12.003.
Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.
聚腺苷二磷酸核糖（PARP）抑制剂的三期临床试验取得成功将对分层癌症治疗产生影响。在本期《细胞化学生物学》中，克内泽维奇等人（2016年）证明，现有的PARP抑制剂集合各自显示出独特的蛋白质相互作用谱，超出了其预期的治疗靶点，对代谢和其他疾病具有影响。
